Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Januar 2018 16:09 ET | Quelle: Ablexis, LLC

Ablexis Announces Licensing of the AlivaMab Mouse to NGM Biopharmaceuticals

BURLINGAME, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a...
14. September 2017 08:01 ET | Quelle: Ablexis, LLC

Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics

BURLINGAME, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a...
14. Februar 2017 08:30 ET | Quelle: Ablexis, LLC

Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen

-- Ablexis Looks Forward to Establishing Additional Non-Exclusive Partnerships in 2017 -- BURLINGAME, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Ablexis, LLC today announced a licensing agreement...
12. Januar 2017 12:07 ET | Quelle: Ablexis, LLC

Ablexis Announces Perpetual License of the AlivaMab Mouse to Tri-Institutional Therapeutics Discovery Institute

BURLINGAME, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) -- Ablexis, LLC announced today that it has entered into a non-exclusive, perpetual license agreement with the Tri-Institutional Therapeutics...